The COBALT-LYM study of CTX130: a phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-Cas9–engineered CAR T cells in patients with relapsed/refractory (R/R) T-cell malignancies
Title:
The COBALT-LYM study of CTX130: a phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-Cas9–engineered CAR T cells in patients with relapsed/refractory (R/R) T-cell malignancies
Author:
Zain, DR Iyer, SP Sica, RA Ho, PJ Hu, B Prica, A Weng, W-K Kim, YH Khodadoust, MS Palomba, ML Foss, FM Tipton, K Cullingford, EL Horwitz, SM Sharma, A Horwitz, SM